Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of VEGFR2, has been approved for the treatment of gastric/gastroesophageal junction and non-small-cell lung and metastatic colorectal cancers [36]. Here, KDR is linked to metastatic colorectal cancer.